ETF Holdings Breakdown of QURE

Stock NameUniqure NV
TickerQURE(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINNL0010696654

News associated with QURE

uniQure (NASDAQ:QURE) Position Lowered by Stifel Financial Corp
Stifel Financial Corp reduced its position in uniQure (NASDAQ:QURE – Free Report) by 7.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,168 shares of the biotechnology company’s stock after selling 4,828 shares during the quarter. Stifel Financial Corp’s […] - 2025-05-09 08:28:58
uniQure (NASDAQ:QURE) Short Interest Up 19.8% in April
uniQure (NASDAQ:QURE – Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 5,260,000 shares, a growth of 19.8% from the March 31st total of 4,390,000 shares. Based on an average daily trading volume, of 1,380,000 shares, the […] - 2025-05-05 07:58:48
uniQure (NASDAQ:QURE) Earns “Buy” Rating from HC Wainwright
uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $70.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 386.45% from […] - 2025-04-23 05:34:42
Pre-Market Most Active for Apr 17, 2025 : HTZ, TSLL, NVDA, TQQQ, SQQQ, QURE, TSM, HIMS, NVO, UNH, BABA, NIO
The NASDAQ 100 Pre-Market Indicator is up 152.15 to 18,409.79. The total Pre-Market volume is currently 187,788,799 shares traded.The following are the most active stocks for the pre-market session: Hertz Global Holdings, Inc (HTZ) is +1.35 at $7.06, with 12,622,622 shares trade - 2025-04-17 12:28:52
Alliancebernstein L.P. Increases Stock Position in uniQure (NASDAQ:QURE)
Alliancebernstein L.P. boosted its holdings in uniQure (NASDAQ:QURE – Free Report) by 14.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 203,919 shares of the biotechnology company’s stock after acquiring an additional 25,319 shares during the quarter. Alliancebernstein L.P.’s holdings in uniQure were worth $3,601,000 as of its most recent filing with […] - 2025-04-15 07:50:49
uniQure (NASDAQ:QURE) Coverage Initiated at Chardan Capital
Equities researchers at Chardan Capital initiated coverage on shares of uniQure (NASDAQ:QURE – Get Free Report) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 257.82% from […] - 2025-04-03 07:26:59
Analysts Set uniQure (NASDAQ:QURE) PT at $38.89
Shares of uniQure (NASDAQ:QURE – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-28 06:56:46
uniQure (NASDAQ:QURE) Rating Increased to Sell at StockNews.com
uniQure (NASDAQ:QURE – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. QURE has been the subject of a number of other research reports. Cantor Fitzgerald lifted their target price on shares of uniQure from $28.00 to $58.00 […] - 2025-03-13 06:26:52
uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright
uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $70.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 478.99% from the stock’s previous close. Several other equities research […] - 2025-03-06 08:56:12
William Blair Predicts uniQure’s Q1 Earnings (NASDAQ:QURE)
uniQure (NASDAQ:QURE – Free Report) – William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of uniQure in a report released on Thursday, February 27th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings of ($1.48) per share for the quarter, down from their prior forecast […] - 2025-03-04 06:33:08
Y Intercept Hong Kong Ltd Lowers Stake in uniQure (NASDAQ:QURE)
Y Intercept Hong Kong Ltd lowered its stake in shares of uniQure (NASDAQ:QURE – Free Report) by 50.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 28,319 shares of the biotechnology company’s stock after selling 29,014 shares during the period. Y Intercept Hong Kong Ltd owned […] - 2025-03-03 08:28:55
uniQure (NASDAQ:QURE) Receives $40.00 Average Price Target from Analysts
Shares of uniQure (NASDAQ:QURE – Get Free Report) have received a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the […] - 2025-02-06 07:00:57

QURE institutional holdings

The following institutional investment holdings of QURE have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 56,693USD 694,489
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 25,317USD 310,133
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 25,317USD 310,133 17.9%
Total =107,327 USD 1,314,755
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.